
Opinion|Videos|March 11, 2024
Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM
Carol Ann Huff, MD, describes her institution's multidisciplinary approach to monitoring for adverse events when administering bispecific antibodies, including the roles of nurses, pharmacists, and attending physicians.
Advertisement
Advertisement
Related to this article

October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.

CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.

VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.

October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.

October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.

Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.

ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Cystatin C and the Future of Kidney Function Assessment
2
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
3
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
4
Nicotine Vaping Linked to Lower Vascular Function in Young Adults
5



